ArticleJAMA network open2026
New-Onset Atrial Fibrillation and Accelerated Kidney Function Decline in Working-Age Adults.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Early identification of cardiovascular-kidney-metabolic (CKM) syndrome is essential for preventing subsequent organ failure. While atrial fibrillation (AF) is often incidentally detected in working-age adults and such detection is a risk for heart failure development, its specific impact on kidney function decline is yet to be elucidated in this young population. Objective: To investigate the association of new-onset AF with subsequent kidney function decline in working-age adults. Design, Setting, and Participants: This retrospective cohort study was conducted using annual health screening records (serial electrocardiogram and estimated glomerular filtration rate [eGFR]) and insurance claims data from April 1, 2015, to March 31, 2023, in Japan. Participants included screening attendees aged 35 to 59 years (working-age population) in sinus rhythm without prior AF, cardiovascular comorbidities, or end-stage kidney disease. Data were analyzed from April 1, 2024, to November 1, 2025. Exposure: Individuals who developed new-onset AF during the annual screening interval were matched 1:5 to those who did not. Main Outcomes: The primary outcome was annual rate of eGFR decline, estimated using linear mixed-effects models. The secondary outcome was a 30% or greater decline in eGFR from baseline, assessed using a Cox proportional hazards model. Results: Among 7 717 526 individuals with sinus rhythm at baseline, 141 060 adults were matched (mean [SD] age, 49.8 [6.6] years; 81.8% male; median [IQR] follow-up, 4.73 [3.50-6.22] years). New-onset AF was associated with a greater annual rate of eGFR decline (-1.23 [95% CI, -1.26 to -1.21] mL/min/1.73 m2) than that of individuals who did not develop AF (-0.94 [95% CI, -0.95 to -0.93] mL/min/1.73 m2), with a difference of -0.29 (95% CI, -0.32 to -0.26) mL/min/1.73 m2 (P < .001). Also, new-onset AF was associated with an increased incidence of a 30% or greater eGFR decline (hazard ratio, 2.91; 95% CI, 2.72-3.11; P < .001). Conclusions and Relevance: In this retrospective cohort study of working-age adults, new-onset AF was associated with an acceleration in kidney function decline. Further investigation is warranted to clarify the impact of AF burden on the decline and to determine the effectiveness of AF treatments for improving kidney outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.